Last reviewed · How we verify
Cytisinicline and exercise
Cytisinicline is a partial agonist of nicotinic acetylcholine receptors that reduces nicotine craving and withdrawal symptoms, combined with exercise to enhance smoking cessation outcomes.
Cytisinicline is a partial agonist of nicotinic acetylcholine receptors that reduces nicotine craving and withdrawal symptoms, combined with exercise to enhance smoking cessation outcomes. Used for Smoking cessation in combination with exercise intervention.
At a glance
| Generic name | Cytisinicline and exercise |
|---|---|
| Also known as | Cytisinicline, Exercise |
| Sponsor | Maimónides Biomedical Research Institute of Córdoba |
| Drug class | Nicotinic acetylcholine receptor partial agonist |
| Target | Nicotinic acetylcholine receptors |
| Modality | Small molecule |
| Therapeutic area | Addiction/Smoking Cessation |
| Phase | FDA-approved |
Mechanism of action
Cytisinicline binds to nicotinic acetylcholine receptors with lower affinity than nicotine, reducing the rewarding effects of smoking and alleviating withdrawal symptoms. When combined with structured exercise, the intervention leverages both pharmacological and behavioral mechanisms to improve quit rates and long-term abstinence in smokers.
Approved indications
- Smoking cessation in combination with exercise intervention
Common side effects
- Nausea
- Headache
- Dizziness
- Insomnia
Key clinical trials
- Screening and Multiple Intervention on Lung Epidemics (PHASE2)
- 12-Month Efficacy of Exercise and Cytisinicline for Tobacco Abstinence (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |